title: Infant botulism: review and clinical update.
abstract: Botulism is a rare neuromuscular condition, and multiple clinical forms are recognized. Infant botulism was first identified in the 1970s, and it typically occurs in infants younger than 1 year of age who ingest Clostridium botulinum spores. A specific treatment for infant botulism, intravenous botulism immunoglobulin (BIG-IV or BabyBIG®), was developed in 2003, and this treatment has substantially decreased both morbidity and hospital costs associated with this illness. This article will review the pathogenesis of infant botulism as well as the epidemiology, clinical manifestations, diagnosis, and treatment of this condition.
authors.affiliation: Department of Neurology, University of California San Francisco, San Francisco, California. Electronic address: laura.rosow@gmail.com.
authors.forename: Laura K
authors.initials: LK
authors.lastname: Rosow
authors.affiliation: Department of Pediatric Neurology, University of California San Francisco, San Francisco, California.
authors.forename: Jonathan B
authors.initials: JB
authors.lastname: Strober
mesh_terms: D001906:Botulism / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007223:Infant
chemical_list: D007136:Immunoglobulins; D007155:Immunologic Factors; C068584:botulism immune globulin
keywords: Clostridium; botulinum; botulism; infant; infantile; paralysis; review